Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research.
Raxibacumab (150 μg/kg or 300 μg/kg for i.v., single dose) significantly improved in outcome when it was administered up to 6 h after rats initial exposure to Bacillus anthracis lethal toxin (LeTx) infusion[3].
References:
[1]. Mazumdar S. Raxibacumab. MAbs.2009 Nov-Dec;1(6):531-8.
[2]. Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist. 2014 Apr 29;7:101-9.
[3]. Cui X, et.al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis. 2005 Feb 1;191(3):422-34.